Co-administration of mirdametinib and lifirafenib for use in treating cancers
The present disclosure relates to methods of treating cancers comprising coadministration of mirdametinib or a pharmaceutically acceptable salt form thereof, and lifirafenib or a pharmaceutically acceptable salt form thereof, to a patient in need thereof. Also disclosed are pharmaceutical compositions of mirdametinib or a pharmaceutically acceptable salt form thereof, and lifirafenib or a pharmaceutically acceptable salt form thereof, for use in such cancer treatment, as well as uses of these compounds for manufacture of medicaments for the treatment of cancers.
1 . A method of treating a patient having a solid tumor comprising co-administering to the patient a therapeutically effective amount of mirdametinib or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of lifirafenib, or a pharmaceutically acceptable salt thereof.
2 . The method of claim 1 , wherein the therapeutically effective amount of mirdametinib is about 1 mg to about 5 mg per day.
3 . The method of claim 1 , wherein the therapeutically effective amount of lifirafenib, or a pharmaceutically acceptable salt thereof, is about 5mg to about 40 mg per day.
4 . The method of claim 1 , wherein mirdametinib is administered once per day.
5 . The method of claim 1 , wherein lifirafenib, or a pharmaceutically acceptable salt thereof, is administered once per day.
6 . The method of claim 1 , wherein the solid tumor is selected from the group consisting of malignant peripheral nerve sheath tumor, biliary tract cancer, breast cancer, cholangiocarcinoma, urothelial cancer, uterine neoplasm, lung adenocarcinoma, squamous non-small cell lung cancer, non-squamous non-small cell lung cancer, gastric cancer, sarcoma, bladder cancer, head and neck cancer, small cell lung cancer, endometrial cancer, esophageal cancer, adenoid cystic carcinoma, gallbladder cancer, colorectal cancer, thyroid cancer, hepatocellular cancer, prostate cancer, oral cancer, cervical cancer, pancreatic carcinoma, ovarian cancer, melanoma, and serous carcinoma to the peritoneum.
7 . The method of claim 6 , wherein the patient has non-small cell lung cancer.
8 . The method of claim 6 , wherein the patient has endometrial cancer.
9 . The method of claim 6 , wherein the patient has ovarian cancer.
10 . The method of claim 9 , where the patient has low grade serous ovarian cancer.
11 . A pharmaceutical composition comprising:
a) mirdametinib, or a pharmaceutically acceptable salt thereof;
b) lifirafenib, or a pharmaceutically acceptable salt thereof;
c) optionally a filler;
d) optionally a disintegrant; and
e) optionally a lubricant.
12 . The pharmaceutical composition of claim 11 , wherein mirdametinib is present at about 0.8 mg to about 1.2 mg.
13 . The pharmaceutical composition of claim 11 , wherein mirdametinib is present at about 1.5 mg to about 2.5 mg.
14 . The pharmaceutical composition of claim 11 , comprising a filler, a disintegrant, and a lubricant.
15 . The pharmaceutical composition of claim 14 , wherein mirdametinib is present at about 0.8 mg to about 1.2 mg.
16 . The pharmaceutical composition of claim 14 , wherein mirdametinib is present at about 1.5 mg to about 2.5 mg.